Navigation Links
Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies

RESEARCH TRIANGLE PARK, N.C., Mar 8, 2007 (CCNMatthews via COMTEX News Network) -- Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Dr. Antonella Perotti, MD, Istituto Nazionale dei Tumori Milano, SENDO Foundation, an investigator in Adherex's European Phase Ib/II study of single-agent ADH-1, will present data today from that study at the 5th International Symposium on Targeted Anticancer Therapies in Amsterdam, The Netherlands.

The data includes 30 patients who received an aggregate of over 200 doses (68 cycles) of ADH-1 given on a weekly schedule with doses ranging from 150 to 2400 mg/m2. ADH-1 was well tolerated at all doses tested for periods of up to eight months, displayed predictable pharmacokinetics, and demonstrated hints of anti-tumor activity in five patients with advanced, chemotherapy-resistant cancer. A maximum tolerated dose was not defined.

"This European data is consistent with our prior clinical experience, showing ADH-1 to be well tolerated over a broad dosage range with hints of anti-tumor activity in a variety of tumor types," said William P. Peters, MD, PhD, Chairman and CEO of Adherex. "Given the unexpected level of synergy of ADH-1 in combination with chemotherapy that we have reported from our preclinical studies, the clinical development of this drug continues fully on track. We expect to have results from the North American Phase II trial with single-agent ADH-1 as well as initial results from our ongoing Phase I combination studies with ADH-1 and chemotherapy available later this year."

In the European Phase Ib/II study, three of 19 patients (16%) with ovarian/gynecological tumors experienced evidence of anti-tumor activity, one with an unconfirmed partial response (previously reported) and two with prolonged stabilization of their disease, which were previously
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Malvern initiates European user group meetings for chemical imaging
7. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
8. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Inspire Announces Presentations at Two European Scientific Conferences
11. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
Post Your Comments:
(Date:8/29/2014)... Research and Markets  has announced the ... Devices Market 2014-2018" report to their offering. ... cells that connect, support, or surround bones. There are ... ligaments, cartilage, fascia, and other fibrous tissues. Repetitive use, ... age result in wear and tear in these tissues. ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Services Industry (U.S.): Analytics, Extensive Financial ... 2021, NAIC 541380 ... Testing Laboratories, Safety and Compliance Services ...
(Date:8/28/2014)... -- Pharmatech initiated enrollment for its AccessPPM program ... for matching cancer patients to cancer clinical trials. ... cancers, disease staging, and genetic mutations - which ... the first place. The challenge that the industry ... well known to the patient or even their ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... The microbiology testing sector is one of the ... is also the hugest challenge facing suppliers during these ... of AIDS – still the world’s key health threat ... opportunistic infections (OIs); bioterrorism threat; advancements in technologies for ... Although for certain infections the etiology remains a mystery, ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Prostate cancer ... good treatment decisions. This can lead to worse quality ... The study included 70 men, with a median age ... cancer. Poor understanding of the disease was associated ... less confidence that the treatment would be effective, the ...
(Date:8/29/2014)... 2014 Edvance360, a leading provider of ... online teaching, as well as 2011 winner and six-time-finalist ... Management System, announced that Brooke Education Services, Northwest Academy, ... Interactive Advertising Bureau of Canada (IAB Canada), StarSVCS, and ... are delighted to welcome each new client to the ...
(Date:8/29/2014)... is a U.S. Food and Drug Administration (FDA)-approved ... raloxifene is as effective at reducing fracture risk ... by suppressing bone loss. With the use of ... respectively), researchers carried out experiments at the U.S. ... at Argonne National Laboratory that revealed an additional ...
Breaking Medicine News(10 mins):Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Revealing a novel mode of action for an osteoporosis drug 2
... ... Roberto Giraldo shows that AIDS is a result of multiple, repeated and chronic exposure to ... and most of all, emotional. , ... Oakland, CA (PRWEB) November 8, 2009 -- From Nov. 6 – 8, 2009, ...
... Nov. 7 Today, the House of Representatives passed ... amendment to the "Affordable Health Care for America Act" ... preventing federal funding for abortion and for benefits packages ... who receive affordability credits and those who do not, ...
... H.R. 3961 to Secure the Stability of Medicare , ... M.D., President, American Medical Association. , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ... the House health reform bill, which will help improve the ... passage of H.R. 3961 to secure the stability of the ...
... Calif., Nov. 8 March of Dimes hosted the ... individuals who are celebrating the birth of their children ... commitment to improve the health of babies. As ... Month campaign, celebrities and special guests were urged to ...
... , Jacquelyn T. Coleman (CT), David A. Cook ... David L. Tarver (LA) Honored , CHICAGO, Nov. ... five medical society executive leaders with achievement awards to ... the medical profession. The awards were presented at the ...
... , WASHINGTON, Nov. 7 The U.S. bishops November ... vote for the Stupak-Ellsworth Amendment to the health care ... current federal law on abortion funding and conscience protections ... 3962)," they said. , The letter was signed by ...
Cached Medicine News:Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Medical Society Executives 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: